LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 109

Search options

  1. Book: Pulmonary pathology

    Cagle, Philip T. / Kerr, Keith M.

    neoplastic and non-neoplastic

    (Encyclopedia of pathology ; Springer reference)

    2018  

    Author's details Philip T. Cagle, Keith M. Kerr editors
    Series title Encyclopedia of pathology
    Springer reference
    Keywords Adenocarcinoma ; Oncocytoma ; Rhabdomyosarcomas ; Coal Worker`s Pneumoconiosis ; Transplant-associated lymphoproliferative disorders
    Subject code 610
    Language English
    Size xxi, 453 Seiten, Illustrationen, 25.4 cm x 17.8 cm
    Publisher Springer International Publishing
    Publishing place Cham
    Publishing country Switzerland
    Document type Book
    HBZ-ID HT019721635
    ISBN 978-3-319-69262-3 ; 3-319-69262-3 ; 9783319692630 ; 3319692631
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    2018 A 918 available for loan (reading room) Lesesaal EG

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Improving practice in PD-L1 testing of non-small cell lung cancer in the UK: current problems and potential solutions.

    Gosney, John R / Peake, Michael D / Kerr, Keith M

    Journal of clinical pathology

    2024  Volume 77, Issue 2, Page(s) 135–139

    Abstract: Aims: Programmed cell death ligand 1 (PD-L1) expression, used universally to predict response of non-small cell lung cancer (NSCLC) to immune-modulating drugs, is a fragile biomarker due to biological heterogeneity and challenges in interpretation. The ... ...

    Abstract Aims: Programmed cell death ligand 1 (PD-L1) expression, used universally to predict response of non-small cell lung cancer (NSCLC) to immune-modulating drugs, is a fragile biomarker due to biological heterogeneity and challenges in interpretation. The aim of this study was to assess current PD-L1 testing practices in the UK, which may help to define strategies to improve its reliability and consistency.
    Methods: A questionnaire covering NSCLC PD-L1 testing practice was devised and members of the Association of Pulmonary Pathologists were invited to complete this online.
    Results: Of 44 pathologists identified as involved in PD-L1 testing, 32 (73%) responded. There was good consistency in practice and approach, but there was wide variability in the distribution of PD-L1 scoring. Although the proportions of scores falling into the three groups (negative, low and high) defined by the 1% and 50% 'cut-offs' (38%, 33% and 27%, respectively) reflect the general experience, the range within each group was wide at 23-70%, 10-60% and 15-36%, respectively.
    Conclusions: There is inconsistency in the crucial endpoint of PD-L1 testing of NSCLC, the expression score that guides management. Addressing this requires formal networking of individuals and laboratories to devise a strategy for its reduction.
    MeSH term(s) Humans ; Carcinoma, Non-Small-Cell Lung/diagnosis ; Carcinoma, Non-Small-Cell Lung/metabolism ; Lung Neoplasms/diagnosis ; Lung Neoplasms/metabolism ; B7-H1 Antigen/metabolism ; Reproducibility of Results ; Immunohistochemistry ; United Kingdom ; Biomarkers, Tumor
    Chemical Substances B7-H1 Antigen ; Biomarkers, Tumor
    Language English
    Publishing date 2024-01-18
    Publishing country England
    Document type Journal Article
    ZDB-ID 80261-x
    ISSN 1472-4146 ; 0021-9746
    ISSN (online) 1472-4146
    ISSN 0021-9746
    DOI 10.1136/jcp-2022-208643
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ud II Zs.139: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Book: Transbronchial and endobronchial biopsies

    Cagle, Philip T. / Allen, Timothy C. / Kerr, Keith M.

    2009  

    Author's details Philip T. Cagle ; Timothy C. Allen ; Keith M. Kerr
    Keywords Lung Diseases / pathology ; Bronchial Diseases / pathology ; Bronchi / pathology ; Lung / pathology ; Biopsy / methods
    Language English
    Size XIII, 168 S. : zahlr. Ill.
    Publisher Wolters Kluwer, Lippincott Williams & Wilkins
    Publishing place Philadelphia u.a.
    Publishing country United States
    Document type Book
    HBZ-ID HT015629973
    ISBN 978-0-7817-8517-4 ; 0-7817-8517-0
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    2008 A 4537 order for loan Magazin
    Zugang zu Internetausgabe aus lizenzrechtlichen Gründen nicht verfügbar

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: The PD-L1 Immunohistochemistry Biomarker: Two Steps Forward, One Step Back?

    Kerr, Keith M

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

    2018  Volume 13, Issue 3, Page(s) 291–294

    MeSH term(s) B7-H1 Antigen ; Biomarkers ; Carcinoma, Non-Small-Cell Lung ; Cell Death ; Humans ; Immunohistochemistry ; Lung Neoplasms ; Nivolumab
    Chemical Substances B7-H1 Antigen ; Biomarkers ; Nivolumab (31YO63LBSN)
    Language English
    Publishing date 2018-02-22
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 2432037-7
    ISSN 1556-1380 ; 1556-0864
    ISSN (online) 1556-1380
    ISSN 1556-0864
    DOI 10.1016/j.jtho.2018.01.020
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6664: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 652: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: ALK testing in non-small cell lung carcinoma: what now?

    Kerr, Keith M

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

    2014  Volume 9, Issue 5, Page(s) 593–595

    MeSH term(s) Biomarkers, Tumor/analysis ; Carcinoma, Non-Small-Cell Lung/chemistry ; Humans ; Immunohistochemistry ; Lung Neoplasms/chemistry ; Receptor Protein-Tyrosine Kinases/analysis
    Chemical Substances Biomarkers, Tumor ; Receptor Protein-Tyrosine Kinases (EC 2.7.10.1) ; anaplastic lymphoma kinase (EC 2.7.10.1)
    Language English
    Publishing date 2014-05
    Publishing country United States
    Document type Comment ; Editorial
    ZDB-ID 2432037-7
    ISSN 1556-1380 ; 1556-0864
    ISSN (online) 1556-1380
    ISSN 1556-0864
    DOI 10.1097/JTO.0000000000000171
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6664: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 652: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Response.

    Perrotta, Fabio / Kerr, Keith M / Navani, Neal

    Chest

    2020  Volume 158, Issue 4, Page(s) 1787–1788

    MeSH term(s) B7-H1 Antigen ; Carcinoma, Non-Small-Cell Lung ; Humans ; Lung Neoplasms ; Ultrasonography, Interventional
    Chemical Substances B7-H1 Antigen
    Language English
    Publishing date 2020-10-06
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 1032552-9
    ISSN 1931-3543 ; 0012-3692
    ISSN (online) 1931-3543
    ISSN 0012-3692
    DOI 10.1016/j.chest.2020.07.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui III Zs.45: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 349: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Clinical relevance of the new IASLC/ERS/ATS adenocarcinoma classification.

    Kerr, Keith M

    Journal of clinical pathology

    2013  Volume 66, Issue 10, Page(s) 832–838

    Abstract: In 2011, recommendations for a multidisciplinary classification of lung adenocarcinoma were published under the auspices of the International Association for the Study of Lung Cancer, the American Thoracic Society and the European Respiratory Society. ... ...

    Abstract In 2011, recommendations for a multidisciplinary classification of lung adenocarcinoma were published under the auspices of the International Association for the Study of Lung Cancer, the American Thoracic Society and the European Respiratory Society. The review was considered necessary due to emerging data on the radiological features, genetics and therapeutic approaches to lung adenocarcinoma, all underpinned by expanding the knowledge of the pathology of this common tumour. The existing WHO classification of 2004 was not really fit for this multidisciplinary focus on the disease. This review describes the recommendations made on the reporting of surgically resected lung cancers according to their predominant pattern, and argues the case for replacing the term bronchioloalveolar carcinoma (WHO 1999 and 2004 definition) with adenocarcinoma in situ and for the introduction of minimally invasive adenocarcinoma. There is also a discussion of diagnosis of non-small-cell lung carcinomas in the small biopsy or cytology setting, a practice that was inadequately addressed in WHO 2004, yet this is much more relevant to most pathologists' daily practice because 85% or so of adenocarcinomas are never resected. Predictive immunohistochemistry, used correctly, can reduce non-specific diagnosis to less than 10% of the cases. Finally, there is an overview of the emerging data on therapeutically relevant lung adenocarcinoma genetics, considering targetable mutations that are now the focus of much activity. The clinical relevance of these changes is discussed.
    MeSH term(s) Adenocarcinoma/classification ; Adenocarcinoma/genetics ; Adenocarcinoma/pathology ; Adenocarcinoma/surgery ; Adenocarcinoma of Lung ; Adenocarcinoma, Bronchiolo-Alveolar/classification ; Adenocarcinoma, Bronchiolo-Alveolar/genetics ; Adenocarcinoma, Bronchiolo-Alveolar/pathology ; Adenocarcinoma, Bronchiolo-Alveolar/surgery ; Humans ; Lung/pathology ; Lung/surgery ; Lung Neoplasms/classification ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Lung Neoplasms/surgery ; Mutation ; Pathology, Molecular
    Language English
    Publishing date 2013-04-06
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 80261-x
    ISSN 1472-4146 ; 0021-9746
    ISSN (online) 1472-4146
    ISSN 0021-9746
    DOI 10.1136/jclinpath-2013-201519
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ud II Zs.139: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.

    Lim, Tony Kiat Hon / Skoulidis, Ferdinandos / Kerr, Keith M / Ahn, Myung-Ju / Kapp, Joshua R / Soares, Fernando A / Yatabe, Yasushi

    Lung cancer (Amsterdam, Netherlands)

    2023  Volume 184, Page(s) 107293

    Abstract: KRAS is the most commonly mutated oncogene in advanced, non-squamous, non-small cell lung cancer (NSCLC) in Western countries. Of the various KRAS mutants, KRAS G12C is the most common variant (~40%), representing 10-13% of advanced non-squamous NSCLC. ... ...

    Abstract KRAS is the most commonly mutated oncogene in advanced, non-squamous, non-small cell lung cancer (NSCLC) in Western countries. Of the various KRAS mutants, KRAS G12C is the most common variant (~40%), representing 10-13% of advanced non-squamous NSCLC. Recent regulatory approvals of the KRAS
    MeSH term(s) Humans ; Carcinoma, Non-Small-Cell Lung/epidemiology ; Carcinoma, Non-Small-Cell Lung/genetics ; Kelch-Like ECH-Associated Protein 1 ; Proto-Oncogene Proteins p21(ras)/genetics ; Prevalence ; Lung Neoplasms/epidemiology ; Lung Neoplasms/genetics ; NF-E2-Related Factor 2 ; Mutation/genetics
    Chemical Substances adagrasib (8EOO6HQF8Y) ; Kelch-Like ECH-Associated Protein 1 ; Proto-Oncogene Proteins p21(ras) (EC 3.6.5.2) ; NF-E2-Related Factor 2 ; KRAS protein, human
    Language English
    Publishing date 2023-07-13
    Publishing country Ireland
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 632771-0
    ISSN 1872-8332 ; 0169-5002
    ISSN (online) 1872-8332
    ISSN 0169-5002
    DOI 10.1016/j.lungcan.2023.107293
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2135: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 423: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Classification of lung cancer: proposals for change?

    Kerr, Keith M

    Archives of pathology & laboratory medicine

    2012  Volume 136, Issue 10, Page(s) 1190–1193

    Abstract: Clinical need and developments in pathology and molecular biology require our cancer classifications to be constantly updated to keep them relevant and useful. A review of lung cancer classification is due and has been initiated with new proposals on ... ...

    Abstract Clinical need and developments in pathology and molecular biology require our cancer classifications to be constantly updated to keep them relevant and useful. A review of lung cancer classification is due and has been initiated with new proposals on classification of lung adenocarcinoma. Other major lung cancer types also deserve a similar consideration. As well as addressing the categories of tumor, as signed out in surgical resection specimens, recent proposals on small diagnostic-sample reporting would be an important addition to any new classification. The huge increase in data on the molecular biology of lung cancer has improved our understanding of these diseases, has driven improved therapy for some patients, and must be reflected in the way lung cancer is classified.
    MeSH term(s) Humans ; Lung Neoplasms/classification ; Lung Neoplasms/pathology
    Language English
    Publishing date 2012-10
    Publishing country United States
    Document type Journal Article
    ZDB-ID 194119-7
    ISSN 1543-2165 ; 0363-0153 ; 0096-8528 ; 0003-9985
    ISSN (online) 1543-2165
    ISSN 0363-0153 ; 0096-8528 ; 0003-9985
    DOI 10.5858/arpa.2012-0240-SA
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ud II Zs.36: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Personalized medicine for lung cancer: new challenges for pathology.

    Kerr, Keith M

    Histopathology

    2012  Volume 60, Issue 4, Page(s) 531–546

    Abstract: Recent advances in non-small-cell lung cancer (NSCLC) therapy mean the relatively simple discrimination between small-cell and 'non-small-cell' carcinoma is insufficient to determine the best treatment for individual patients. Safety, efficacy and ... ...

    Abstract Recent advances in non-small-cell lung cancer (NSCLC) therapy mean the relatively simple discrimination between small-cell and 'non-small-cell' carcinoma is insufficient to determine the best treatment for individual patients. Safety, efficacy and prescribing requirements mandate more specific subtyping of NSCLC for several new drugs: practice made difficult by the tumour heterogeneity combined with the paucity of tissue in most diagnostic samples. Immunohistochemical approaches have emerged as accurate predictors of probable tumour histotype. P63 and/or cytokeratins 5 and 6 and thyroid transcription factor 1 (TTF1) are among the best predictors, respectively, of squamous and adenocarcinoma histology. Molecular characteristics may predict response to both newer molecular targeted agents and traditional cytotoxic agents. Specific mutations in the epidermal growth factor receptor (EGFR) gene as predictors of response to EGFR tyrosine kinase inhibitors (erlotinib, gefitinib) is the first example of markers which predict response to targeted agents. Actual drug targets [e.g. thymidilate synthase (TS) - pemetrexed] or markers of the tumour's ability to repair cytotoxic drug-induced damage [e.g. excision repair cross-complementation group 1 (ERCC1) - cisplatin] may well also complement NSCLC diagnosis. This extended diagnostic requirement from increasingly limited material provided by minimally invasive biopsy techniques poses major challenges for pathology.
    MeSH term(s) Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Carcinoma, Non-Small-Cell Lung/therapy ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Lung Neoplasms/therapy ; Precision Medicine
    Language English
    Publishing date 2012-03
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 131914-0
    ISSN 1365-2559 ; 0309-0167
    ISSN (online) 1365-2559
    ISSN 0309-0167
    DOI 10.1111/j.1365-2559.2011.03854.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1328: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top